Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Expression of Matrix Metalloproteinase 13, Tissue Inhibitor of Metalloproteinases 3, and Calcium-sensing Receptor in Human Trabecular Meshwork

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02638181
Recruitment Status : Completed
First Posted : December 23, 2015
Last Update Posted : January 10, 2017
Sponsor:
Information provided by (Responsible Party):
Lv Yingjuan, Tianjin Medical University Eye Hospital

Tracking Information
First Submitted Date  ICMJE December 14, 2015
First Posted Date  ICMJE December 23, 2015
Last Update Posted Date January 10, 2017
Study Start Date  ICMJE July 2013
Actual Primary Completion Date December 2015   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: December 17, 2015)
the expressions of matrix metalloproteinase 13 and calcium-sensing receptor [ Time Frame: one hour after operation ]
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: December 17, 2015)
histological changes of trabecular meshwork [ Time Frame: one hour after operation ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE The Expression of Matrix Metalloproteinase 13, Tissue Inhibitor of Metalloproteinases 3, and Calcium-sensing Receptor in Human Trabecular Meshwork
Official Title  ICMJE The Expression of Matrix Metalloproteinase 13(MMP13), Tissue Inhibitor of Metalloproteinases 3(TIMP13), and Calcium-sensing Receptor(CaSR) in Human Trabecular Meshwork
Brief Summary This study was to assess the distinct expression of matrix metalloproteinase 13,tissue inhibitor of metalloproteinases 3, and calcium-sensing receptor, in human trabecular meshwork between normal and glaucomatous eyes.The expressions of matrix metalloproteinase 13, tissue inhibitor of metalloproteinases 3 and calcium-sensing receptor in the trabecular meshwork tissues were examined by streptavidin-peroxidase immunohistochemical staining method and western blot, and histological changes of trabecular meshwork were studied by Hematoxylin and Eosin staining.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Condition  ICMJE Open-angle Glaucoma
Intervention  ICMJE Procedure: trabeculectomy
Study Arms  ICMJE Experimental: trabeculectomy
Intervention: Procedure: trabeculectomy
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: January 8, 2017)
60
Original Actual Enrollment  ICMJE
 (submitted: December 17, 2015)
40
Actual Study Completion Date  ICMJE December 2015
Actual Primary Completion Date December 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • intraocular pressure greater than 22 mmHg with two or more medications
  • wide anterior chamber angle
  • glaucomatous optic neuropathy (Glaucomatous optic nerve damage was defined as cup-to-disc ratio higher than 0.7 or focal loss of the nerve fiber layer (notch) associated with a consistent glaucomatous visual field defect
  • visual field loss consistent with optic nerve damage and visual fields were performed by using standard automated perimetry

Exclusion Criteria:

  • the presence of any secondary form of glaucoma including exfoliation syndrome or a history of ocular trauma, etc
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 50 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE China
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02638181
Other Study ID Numbers  ICMJE tjykdxykyy3
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Lv Yingjuan, Tianjin Medical University Eye Hospital
Study Sponsor  ICMJE Lv Yingjuan
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: xiaorong li Tianjin Medical University Eye Hospital
PRS Account Tianjin Medical University Eye Hospital
Verification Date January 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP